139 related articles for article (PubMed ID: 37102488)
1. The Future is Now for Precision Genomic Addiction Medicine as a Frontline Modality for Inducing "Dopamine Homeostasis" in Reward Deficiency Syndrome (RDS).
Gilley ED; Bowirrat A; Gupta A; Giordano J; A Dennen C; R Braverman E; D Badgaiyan R; McLaughlin T; Baron D; Blum K
Curr Pharm Biotechnol; 2023 Apr; ():. PubMed ID: 37102488
[TBL] [Abstract][Full Text] [Related]
2. A Novel Precision Approach to Overcome the "Addiction Pandemic" by Incorporating Genetic Addiction Risk Severity (GARS) and Dopamine Homeostasis Restoration.
Blum K; Kazmi S; Modestino EJ; Downs BW; Bagchi D; Baron D; McLaughlin T; Green R; Jalali R; Thanos PK; Elman I; Badgaiyan RD; Bowirrat A; Gold MS
J Pers Med; 2021 Mar; 11(3):. PubMed ID: 33809702
[TBL] [Abstract][Full Text] [Related]
3. Biotechnical development of genetic addiction risk score (GARS) and selective evidence for inclusion of polymorphic allelic risk in substance use disorder (SUD).
Blum K; Bowirrat A; Baron D; Lott L; Ponce JV; Brewer R; Siwicki D; Boyett B; Gondre-Lewis MC; Smith DE; Panayotis K T; Badgaiyan S; Hauser M; Fried L; A R; Downs BW; Badgaiyan RD
J Syst Integr Neurosci; 2020 Aug; 6(2):. PubMed ID: 33614164
[TBL] [Abstract][Full Text] [Related]
4. Genetic Addiction Risk Score (GARS): molecular neurogenetic evidence for predisposition to Reward Deficiency Syndrome (RDS).
Blum K; Oscar-Berman M; Demetrovics Z; Barh D; Gold MS
Mol Neurobiol; 2014 Dec; 50(3):765-96. PubMed ID: 24878765
[TBL] [Abstract][Full Text] [Related]
5. Dopamine Genetics and Function in Food and Substance Abuse.
Blum K; Oscar-Berman M; Barh D; Giordano J; Gold M
J Genet Syndr Gene Ther; 2013 Feb; 4(121):. PubMed ID: 23543775
[TBL] [Abstract][Full Text] [Related]
6. Should Reward Deficiency Syndrome (RDS) Be Considered an Umbrella Disorder for Mental Illness and Associated Genetic and Epigenetic Induced Dysregulation of Brain Reward Circuitry?
Blum K; Dennen CA; Elman I; Bowirrat A; Thanos PK; Badgaiyan RD; Downs BW; Bagchi D; Baron D; Braverman ER; Gupta A; Green R; McLaughlin T; Barh D; Gold MS
J Pers Med; 2022 Oct; 12(10):. PubMed ID: 36294858
[TBL] [Abstract][Full Text] [Related]
7. A Review of DNA Risk Alleles to Determine Epigenetic Repair of mRNA Expression to Prove Therapeutic Effectiveness in Reward Deficiency Syndrome (RDS): Embracing "Precision Behavioral Management".
Blum K; Steinberg B; Gondre-Lewis MC; Baron D; Modestino EJ; Badgaiyan RD; Downs BW; Bagchi D; Brewer R; McLaughlin T; Bowirrat A; Gold M
Psychol Res Behav Manag; 2021; 14():2115-2134. PubMed ID: 34949945
[TBL] [Abstract][Full Text] [Related]
8. Reward Deficiency Syndrome (RDS): A Cytoarchitectural Common Neurobiological Trait of All Addictions.
Blum K; Bowirrat A; Braverman ER; Baron D; Cadet JL; Kazmi S; Elman I; Thanos PK; Badgaiyan RD; Downs WB; Bagchi D; Llanos-Gomez L; Gold MS
Int J Environ Res Public Health; 2021 Nov; 18(21):. PubMed ID: 34770047
[TBL] [Abstract][Full Text] [Related]
9. Reward Deficiency Syndrome (RDS) Surprisingly Is Evolutionary and Found Everywhere: Is It "Blowin' in the Wind"?
Blum K; McLaughlin T; Bowirrat A; Modestino EJ; Baron D; Gomez LL; Ceccanti M; Braverman ER; Thanos PK; Cadet JL; Elman I; Badgaiyan RD; Jalali R; Green R; Simpatico TA; Gupta A; Gold MS
J Pers Med; 2022 Feb; 12(2):. PubMed ID: 35207809
[TBL] [Abstract][Full Text] [Related]
10. Neurogenetic Impairments of Brain Reward Circuitry Links to Reward Deficiency Syndrome (RDS): Potential Nutrigenomic Induced Dopaminergic Activation.
Blum K; Oscar-Berman M; Giordano J; Downs B; Simpatico T; Han D; Femino J
J Genet Syndr Gene Ther; 2012 Oct; 3(4):. PubMed ID: 23264886
[TBL] [Abstract][Full Text] [Related]
11. Hypothesizing That Neuropharmacological and Neuroimaging Studies of Glutaminergic-Dopaminergic Optimization Complex (KB220Z) Are Associated With "Dopamine Homeostasis" in Reward Deficiency Syndrome (RDS).
Blum K; Febo M; Fried L; Li M; Dushaj K; Braverman ER; McLaughlin T; Steinberg B; Badgaiyan RD
Subst Use Misuse; 2017 Mar; 52(4):535-547. PubMed ID: 28033474
[TBL] [Abstract][Full Text] [Related]
12. Precision Behavioral Management (PBM) and Cognitive Control as a Potential Therapeutic and Prophylactic Modality for Reward Deficiency Syndrome (RDS): Is There Enough Evidence?
Madigan MA; Gupta A; Bowirrat A; Baron D; Badgaiyan RD; Elman I; Dennen CA; Braverman ER; Gold MS; Blum K
Int J Environ Res Public Health; 2022 May; 19(11):. PubMed ID: 35681980
[TBL] [Abstract][Full Text] [Related]
13. Summary Document Research on RDS Anti-addiction Modeling: Annotated Bibliography.
Blum K; Baron D; McLaughlin T; Thanos PK; Dennen C; Ceccanti M; Braverman ER; Sharafshah A; Lewandrowski KU; Giordano J; Badgaiyan RD
J Addict Psychiatry; 2024 Apr; 8(1):1-33. PubMed ID: 38765881
[TBL] [Abstract][Full Text] [Related]
14. The Benefits of Genetic Addiction Risk Score (GARS
Blum K; Modestino EJ; Gondre-Lewis M; Chapman EJ; Neary J; Siwicki D; Baron D; Hauser M; Smith DE; Roy AK; Thanos PK; Steinberg B; McLaughlin T; Fried L; Barh D; Dunston GA; Badgaiyan RD
Int J Genom Data Min; 2018; 2018(1):. PubMed ID: 30198022
[TBL] [Abstract][Full Text] [Related]
15. In Search of Reward Deficiency Syndrome (RDS)-free Controls: The "Holy Grail" in Genetic Addiction Risk Testing.
Blum K; Baron D; Lott L; Ponce JV; Siwicki D; Boyett B; Steinberg B; Modestino EJ; Fried L; Hauser M; Simpatico T; Downs BW; McLaughlin T; Hajela R; Badgaiyan RD
Curr Psychopharmacol; 2020; 9(1):7-21. PubMed ID: 32432025
[TBL] [Abstract][Full Text] [Related]
16. Pro-Dopamine Regulator (KB220) A Fifty Year Sojourn to Combat Reward Deficiency Syndrome (RDS): Evidence Based Bibliography (Annotated).
Kenneth B; Edward MJ; Marjorie GLC; David B; Bruce S; Panayotis TK; William DB; Davis S; Lisa L; Eric BR; Mark M; David M; Lyle F; Rajendra BD
CPQ Neurol Psychol; 2018; 1(2):. PubMed ID: 30957097
[TBL] [Abstract][Full Text] [Related]
17. DNA Directed Pro-Dopamine Regulation Coupling Subluxation Repair, H-Wave
Bajaj A; Blum K; Bowirrat A; Gupta A; Baron D; Fugel D; Nicholson A; Fitch T; Downs BW; Bagchi D; Dennen CA; Badgaiyan RD
J Pers Med; 2022 Aug; 12(9):. PubMed ID: 36143203
[TBL] [Abstract][Full Text] [Related]
18. Genetic Addiction Risk Severity Assessment Identifies Polymorphic Reward Genes as Antecedents to Reward Deficiency Syndrome (RDS) Hypodopaminergia's Effect on Addictive and Non-Addictive Behaviors in a Nuclear Family.
Dennen CA; Blum K; Bowirrat A; Thanos PK; Elman I; Ceccanti M; Badgaiyan RD; McLaughlin T; Gupta A; Bajaj A; Baron D; Downs BW; Bagchi D; Gold MS
J Pers Med; 2022 Nov; 12(11):. PubMed ID: 36579592
[TBL] [Abstract][Full Text] [Related]
19. Neurogenetics and Nutrigenomics of Neuro-Nutrient Therapy for Reward Deficiency Syndrome (RDS): Clinical Ramifications as a Function of Molecular Neurobiological Mechanisms.
Blum K; Oscar-Berman M; Stuller E; Miller D; Giordano J; Morse S; McCormick L; Downs WB; Waite RL; Barh D; Neal D; Braverman ER; Lohmann R; Borsten J; Hauser M; Han D; Liu Y; Helman M; Simpatico T
J Addict Res Ther; 2012 Nov; 3(5):139. PubMed ID: 23926462
[TBL] [Abstract][Full Text] [Related]
20. Would induction of dopamine homeostasis via coupling genetic addiction risk score (GARS®) and pro-dopamine regulation benefit benzodiazepine use disorder (BUD)?
Blum K; Gold M; Modestino EJ; Baron D; Boyett B; Siwicki D; Lott L; Podesta A; Roy AK; Hauser M; Downs BW; Badgaiyan RD
J Syst Integr Neurosci; 2018 May; 4():. PubMed ID: 31750006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
